Recital 1, Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December…

In forcesince 16 Dec 1999cited 4×

some conditions occur so infrequently that the cost of developing and bringing to the market a medicinal product to diagnose, prevent or treat the condition would not be recovered by the expected sales of the medicinal product; the pharmaceutical industry would be unwilling to develop the medicinal product under normal market conditions; these medicinal products are called "orphan";

  • Judgment of the General Court (Tenth Chamber) of 23 September 2020 (Extracts). Medac Gesellschaft für klinische Spezialpräparate mbH v EuropDecision

    Regard being had to the fact that some conditions occur so infrequently that the pharmaceutical industry would be unwilling to develop medicinal products to diagnose, prevent or treat them under normal market conditions (recital 1 of …

    23 Sep 2020 · 62019TJ0549

  • Judgment of the General Court (Fifth Chamber, Extended Composition) of 24 September 2025. Sanofi BV, anciennement Genzyme Europe BV v EuropeDecision

    It is apparent from recitals 1 and 2 of Regulation No 141/2000 that the European Union is seeking to stimulate the research, development and bringing to the market of appropriate medications by the pharmaceutical industry for conditions …

    24 Sep 2025 · 62022TJ0483

  • Judgment of the General Court (Fifth Chamber) of 9 September 2010. CSL Behring GmbH v European Commission and European Medicines Agency (EMADecision

    Fourthly, it is apparent from recitals 1, 2 and 4 in the preamble to Regulation No 141/2000 that the intention of the legislature was to provide for measures to stimulate the research and development of potential orphan medicinal products …

    9 Sep 2010 · 62007TJ0264

  • Opinion of Advocate General Hogan delivered on 11 September 2019. PTC Therapeutics International Ltd v European Medicines Agency.Decision

    The concept of orphan medicinal products is perhaps best explained by the first and second recitals to Regulation No 141/2000: ’Whereas: some conditions occur so infrequently that the cost of developing and bringing to the market a …

    11 Sep 2019 · 62018CC0175